申请人:JCR Pharmaceuticals Co., Ltd.
公开号:EP3508474A1
公开(公告)日:2019-07-10
A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.
本研究提供了一种可抑制持续性低血糖等副作用发生的糖尿病贵族治疗剂。其活性成分是 1,1-二苯基亚氨基脲或 1,1-二苯基硫代氨基脲的衍生物。特别是,活性成分是 1,1-二苯基-4-环己基-氨基脲或 1,1-二苯基-4-环己基-硫代氨基脲的衍生物,口服时具有降血糖作用。